267 related articles for article (PubMed ID: 38263684)
1. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Iwaki M; Fujii H; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T
Clin Mol Hepatol; 2024 Apr; 30(2):225-234. PubMed ID: 38263684
[TBL] [Abstract][Full Text] [Related]
2. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
[TBL] [Abstract][Full Text] [Related]
4. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
5. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performances of Fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction-associated steatotic liver disease in Asian primary care clinics.
Park H; Kim M; Kim HL; Cho S; Yoon EL; Jun DW
Hepatol Res; 2024 May; ():. PubMed ID: 38703383
[TBL] [Abstract][Full Text] [Related]
7. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
[TBL] [Abstract][Full Text] [Related]
8. From NAFLD to MASLD: When metabolic comorbidity matters.
Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H
Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250
[TBL] [Abstract][Full Text] [Related]
9. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.
Suzuki K; Tamaki N; Kurosaki M; Takahashi Y; Yamazaki Y; Uchihara N; Tanaka Y; Miyamoto H; Yamada M; Keitoku T; Okada R; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Izumi N
Hepatol Res; 2024 Jun; 54(6):600-605. PubMed ID: 38234088
[TBL] [Abstract][Full Text] [Related]
10. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
Targher G; Byrne CD; Tilg H
Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
Ishiba H; Sumida Y; Kamada Y; Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Tsutsumi T; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Takahashi H; Ueda S; Aishima S; Nakajima A; Okanoue T;
J Gastroenterol Hepatol; 2023 Jun; 38(6):896-904. PubMed ID: 36797989
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.
Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Kawada N; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):370-379. PubMed ID: 35051649
[TBL] [Abstract][Full Text] [Related]
13. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
Younossi ZM; Golabi P; Price JK; Owrangi S; Gundu-Rao N; Satchi R; Paik JM
Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38521116
[TBL] [Abstract][Full Text] [Related]
14. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
15. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
[TBL] [Abstract][Full Text] [Related]
16. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
[TBL] [Abstract][Full Text] [Related]
17. Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: A multicenter study in Japan.
Tsutsumi T; Kawaguchi T; Fujii H; Kamada Y; Takahashi H; Kawanaka M; Sumida Y; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Ueda S; Aishima S; Nakajima A; Okanoue T
Aliment Pharmacol Ther; 2024 Jun; 59(12):1559-1570. PubMed ID: 38651312
[TBL] [Abstract][Full Text] [Related]
18. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
Canivet CM; Faure S
Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
[TBL] [Abstract][Full Text] [Related]
20. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
Loomba R; Wong VW
Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]